SCHEMBL1454579

SCHEMBL1454579

Cc1ccc(NC(=O)c2ccc(Sc3ccc(NC(=O)OC(C)(C)C)cc3)c(N)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
HPGD P15428 5/20 0.58
ALDH1A1 P00352 4/20 0.58
KDM4E B2RXH2 4/20 0.58
LMNA P02545 3/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
ALOX15 P16050 1/20 0.58
MAPK1 P28482 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TP53 P04637 4/20 0.48
NAMPT P43490 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
STAT3 P40763 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455205 0.91 MAPT (0.46) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL15912554 0.87 MAPT (0.51) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1455518 0.86 NAMPT (0.46) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1455451 0.86 KDM4E (0.65) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1454029 0.85 MAPT (0.45) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL13305748 0.82 MAP4K4 (0.53) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1456097 0.81 MEN1 (0.42) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1456099 0.81 MEN1 (0.42) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1454476 0.81 NAMPT (0.41) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL1454582 0.81 NAMPT (0.46) MAPTL3MBTL1MAPK1NAMPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885HPGD 3704/4885ALDH1A1 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.